ethanolamine
Trade name: ethamolin
Approved
Dec 22, 1988
Ethanolamine oleate is a salt of ethanolamine, a basic substance, and oleic acid. It is marketed under a trade name of Ethamoline as a sclerotic agent for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. In vitro studies revealed that ethanolamine oleate inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent ethanolamine. Nevertheless, from in vivo studies it was suggested that intravascular injection of ethamoline activates the local coagulation system. The activation may be accelerated by an acute inflammatory process provoked by oleate, which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma fibrinogen level. — NCATS
Clinical trial activity
5 trials · 6 clinical orgs · 1 marketing orgs
Earliest trial started Jan 1, 2016 (NCT03388125)
Timeline
1980s
- Mar 22, 1984
Orphan Drug Designation
- Dec 22, 1988
QOL Medical, LLC — Earliest FDA Approval
- Dec 22, 1988
QOL Medical, LLC — NDA Organization
- Dec 22, 1988
QOL Medical, LLC — NDA Secondary Org
Indications
Approved for
Mechanism of action
- Unspecified targetSurfactant
surfactant
Approval history
- approvedPriority reviewDec 22, 1988
Chemistry & pharmacology
SMILES
NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O- Mol. weight
- 343.5444 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEthanolamine ↗
- NCATSU4RY8MRX7C ↗
- ChEMBLCHEMBL1200394 ↗
- WikipediaPhosphorylethanolamine ↗
Also known as
- beta-hydroxyethylammonium oleate
- beta-hydroxyethylammonium oleate
- calcium 2-aminoethanol phosphate
- ethamolin
- ethamolin
- ethamolin
- ethamolin
- ethamolin
- ethanolamine
- ethanolamine
- ethanolamine
- ethanolamine oleate
- ethanolamine oleate
- ethanolamine oleate
- ethanolamine oleate
- ethanolamine oleate
- ethanolamine oleate
- ethanolamine phosphate
- monoethanolamine oleate
- monoethanolamine oleate
- monoethanolamine oleate
- oldamin
- oldamin
- oleic acid, 2-aminoethyl ester
- phosphoethanolamine
- phosphoethanolamine
- phosphoethanolamine
- phosphorylethanolamine
- phosphorylethanolamine, 3h-labeled cpd
- phosphorylethanolamine ca (1:1) salt
- phosphorylethanolamine, cobalt (2+) (1:1) salt
- phosphorylethanolamine magnesium (1:1) salt
- phosphorylethanolamine zinc salt
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07199673 | N/A | Jul 7, 2025 | Gulab Devi Hospital |
| NCT06325982 | N/A | Jun 11, 2024 | Fujian Medical University |
| NCT05797623 | Phase 2 | Apr 26, 2023 | Hengrui Therapeutics, Inc. |
| NCT02950103 | Phase 2 | Aug 1, 2016 | Instituto do Cancer do Estado de São Paulo, Secretaria de Estado da Saúde |
| NCT03388125 | Phase 3 | Jan 1, 2016 | Tanta University |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Gulab Devi Hospital | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2023 |
| Instituto do Cancer do Estado de São Paulo | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Secretaria de Estado da Saúde | Government | 1 | 1 | 1 | 2016 |
| Tanta University | Academic/Hospital | 1 | 1 | 1 | 2016 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| QOL Medical, LLC | For profit | NDA | Dec 22, 1988 |
| QOL Medical, LLC | For profit | NDA2 | Dec 22, 1988 |